Akari Therapeutics (ADR) (AKTX)
Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027
Akari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average – Here’s What Happened
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.24 and traded as low as $7.19. Akari Therapeutics shares last traded at $7.36, with a volume of 24,072 shares traded. Wall Street Analysts Forecast Growth
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments.
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O.
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor “What This Means” interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pancreatic cancer models.
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data supports the broader applicability of targeting RNA splicing to attack difficult-to-treat KRAS-driven cancers
Akari Therapeutics Announces $5.5 Million Private Placement Offering
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial.
Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Increases By 151.7%
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) saw a significant growth in short interest in April. As of April 15th, there was short interest totaling 14,622 shares, a growth of 151.7% from the March 31st total of 5,810 shares. Based on an average trading volume of 45,393 shares, the days-to-cover ratio is presently 0.3
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla. and LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033 1 TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.
Akari Therapeutics Announces ADS Ratio Change
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one ADS representing eighty thousand (80,000) ordinary shares. The ratio change is expected to be effective on March 31, 2026.
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 209,369 shares, a decrease of 16.1% from the February 12th total of 249,671 shares. Approximately 0.7% of the shares of the stock are sold short. Based
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline
Akari Therapeutics (NASDAQ:AKTX) Stock Passes Above 50-Day Moving Average – Here’s Why
Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.26 and traded as high as $0.2773. Akari Therapeutics shares last traded at $0.2570, with a volume of 760,478 shares traded. Analysts Set New